For millions of Americans, overactive bladder (OAB) and erectile dysfunction (ED) are daily struggles that standard medications fail to resolve. While oral drugs help many patients, a significant number either do not respond adequately or cannot tolerate side effects such as dry mouth, constipation, or headaches. Modern urology now offers powerful alternatives beyond pills. From FDA-approved gene therapy and battery-free neuromodulation to advanced penile implants, patients with refractory OAB and ED have more options than ever before.
At Adult & Pediatric Urology, we follow these technological breakthroughs closely. Before considering advanced therapies, many men first review Why Sildenafil Doesn’t Work – 7 Common Reasons and Solutions to understand why oral medications may fail. Others find that Comparing Erectile Dysfunction Medications: Viagra, Cialis, Levitra, and Stendra helps set realistic expectations for first-line treatment.
Why Standard Medications Are Not Enough
Current guidelines from the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) recommend a stepwise approach to overactive bladder. First-line therapy includes bladder training, pelvic floor exercises, and fluid management. Second-line therapy includes antimuscarinics (oxybutynin, tolterodine) and beta-3 agonists (mirabegron). Third-line options for severe, refractory symptoms include Botox injections, percutaneous tibial nerve stimulation, and sacral neuromodulation.
For erectile dysfunction, first-line treatment involves PDE5 inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil. However, up to 30% of men do not respond adequately. Erectile Dysfunction Causes, Symptoms, Diagnosis & Treatment explains why underlying conditions like diabetes, low testosterone, or nerve damage can reduce drug efficacy. For these individuals, second-line options (injections, vacuum devices) and third-line options (penile implants) become essential. Personalized Medical Treatment at Our Urology emphasizes that a tailored approach is key when standard therapies fail.
Gene Therapy for Overactive Bladder: URO-902
Overactive bladder affects approximately one in five women in the United States and is characterized by urinary urgency, frequency, and often urge incontinence. When behavioral and oral medications fail, patients historically had limited options. Now, an investigational gene therapy called URO-902 offers a completely new mechanism of action.
How URO-902 Works
URO-902 is a non-viral plasmid DNA that contains the human gene encoding the large-conductance calcium-activated potassium (BK) channel. The therapy is injected directly into the bladder wall using a cystoscope under local anesthesia. Once inside the smooth muscle cells, the plasmid DNA produces BK channels that help relax the detrusor muscle, reducing involuntary contractions that cause urgency and frequency. Rather than blocking nerve signals, URO-902 targets the root cause of OAB at the molecular level.
Phase 2a Trial Results
A randomized, double-blind, placebo-controlled phase 2a trial (NCT04211831) enrolled 80 women aged 40 to 79 with OAB and urge incontinence who were refractory to at least one OAB medication. Participants received a single injection of URO-902 24 mg, URO-902 48 mg, or placebo. At week 12, the results were significant:
- Daily urinations decreased by 2.3 in the 24-mg group and 2.4 in the 48-mg group, compared with 0.8 in the placebo group (p = 0.017 and p = 0.009).
- Daily urgency episodes decreased by 3.4 in the 48-mg group versus 1.1 in the placebo group (p = 0.016).
- Patient Global Impression of Change showed 58% of patients in the 48-mg group were responders, compared with 31% in the placebo group (p = 0.026).
Although the reduction in urge incontinence episodes did not reach statistical significance, 50% of patients in both URO-902 groups achieved at least a 50% reduction in incontinence episodes versus 35% in the placebo arm. The treatment was safe and well tolerated, with no serious adverse events related to URO-902.
What This Means for Patients
While URO-902 remains investigational and not yet FDA-approved, the phase 2a data represent a major proof-of-concept. For women who have tried multiple OAB medications without success, gene therapy may eventually offer a durable, single-injection alternative. Women with Urinary Incontinence – How Our Clinic Restores Bladder Control may find that current options are insufficient, making future gene therapy an attractive prospect.
Wireless Sacral Neuromodulation: Neuspera iSNM
Sacral neuromodulation has been a third-line treatment for overactive bladder for over two decades. Traditional SNM devices (such as InterStim) require implanting a battery-powered neurostimulator in the buttock with leads connected to the sacral nerve. While effective, these systems have significant drawbacks: battery replacement surgery every 3-5 years, visible bulging, discomfort, and risks of infection, seroma, and hematoma.
The First Battery-Free, Wireless SNM System
On June 18, 2025, the FDA approved Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for urinary urge incontinence. The Neuspera system represents a fundamental redesign. A miniaturized, battery-free neurostimulator is implanted near the sacral nerve. Therapy is activated using an external disc worn against the lower back for about two hours daily. The disc wirelessly charges the implant, and no implanted battery ever needs replacement.
Dr. Howard Goldman of the Cleveland Clinic called the approval “a major advancement,” noting that patients have long worried about battery-related complications.
Six-Month Pivotal Trial Results
A phase II pivotal study enrolled 128 patients with urgency incontinence refractory to behavioral and drug therapy. At six months:
- 84.2% of implanted patients achieved at least a 50% reduction in urgent leaks.
- 84% of responders were “super responders” (more than 75% reduction).
- 42% became completely dry (100% reduction).
- Quality of life improved 3.5-fold.
Dr. Andrea Pezzella, a urogynecologist, describes Neuspera as a “smart, integrated, sophisticated alternative” that removes the burden of battery replacement surgeries.
Comparison with Traditional SNM
| Feature | Traditional SNM | Neuspera iSNM |
|---|---|---|
| Battery | Implanted (3-5 years) | None (wireless) |
| Replacement surgery | Required every 3-5 years | Never required |
| Daily wear | None | External disc, ~2 hours |
| Efficacy (≥50% reduction) | 70-85% | 84.2% |
For men with urinary symptoms, the Root can help distinguish OAB from other conditions. Those experiencing Urinary Urgency and Urge Incontinence may find that neuromodulation offers relief when medications fail.
Penile Implants for Erectile Dysfunction
For men with erectile dysfunction who do not respond to oral medications, injections, or vacuum devices, penile implants (penile prostheses) remain the gold standard third-line therapy. These devices are mechanical and do not affect libido, orgasm, or ejaculation.
Types of Penile Implants
- Inflatable penile prosthesis (IPP): Paired cylinders in the corpora cavernosa, a pump in the scrotum, and a fluid reservoir in the abdomen. Squeezing the pump creates an erection; a release valve deflates. IPPs produce the most natural erections.
- Semi-rigid rods: Bendable rods that are always firm. Simpler and less prone to mechanical failure, but erections are less natural.
Success Rates and Satisfaction
Penile implants have the highest satisfaction rates of any ED treatment – over 90% of men and their partners report satisfaction. Mechanical failure rates are about 5% at 5 years and 10-15% at 10 years for modern IPPs. Complications include infection (1-3%), mechanical malfunction, and erosion.
For men with severe, medication-refractory ED, a penile implant restores reliable erections on demand. Erectile Dysfunction Generics – Side Effects, What Men Should Know and When to Seek Care often leads patients to realize that generics are insufficient. Tadalafil for Erectile Dysfunction – Vidalista, Daily Use, and Alternatives may work for some, but non-responders should consider implants. Even advanced oral options like Stendra (Avanafil) – The Next-Gen Erectile Dysfunction Medication or Levitra (Vardenafil) cannot help every man. When all oral agents fail, a penile implant provides a reliable solution.
Comparison of Third-Line Therapies
| Therapy | Condition | Mechanism | Procedure | Duration | Common Side Effects |
|---|---|---|---|---|---|
| URO-902 (gene therapy) | OAB (investigational) | BK channel expression | Single bladder injection | ≥12 weeks | UTI, hematuria (mild) |
| Neuspera iSNM | OAB/UUI | Wireless sacral neuromodulation | Implant near sacral nerve | Years | Site pain, infection (2-3%) |
| Traditional SNM | OAB/UUI | Battery-powered neuromodulation | Buttock implant + lead | 3-5 years | Battery site pain, infection |
| Penile implant (IPP) | ED | Hydraulic cylinders | Surgery under anesthesia | 10-15+ years | Infection, mechanical failure |
Frequently Asked Questions
Is URO-902 gene therapy available now?
No. URO-902 is still investigational and has completed phase 2a trials. Phase 3 trials are needed before FDA approval. The results are promising for women with refractory OAB.
How long does the Neuspera iSNM implant last?
The implant itself lasts many years without replacement because it has no battery. The external disc is worn daily for about two hours and can be replaced if lost or damaged.
Are penile implants covered by insurance?
Yes. Medicare and most private insurers cover penile implants for medically diagnosed erectile dysfunction that has not responded to less invasive treatments. Prior authorization is usually required.
Can women receive neuromodulation for OAB?
Absolutely. Both traditional SNM and Neuspera iSNM are approved for women with urgency incontinence and overactive bladder. Most clinical trials have predominantly enrolled women.
Which therapy is best for me if pills don’t work?
There is no single answer. The best therapy depends on your specific condition, anatomy, preferences, and overall health. Our team at Adult & Pediatric Urology can help you weigh the pros and cons.
Medical Disclaimer
The information provided in this article is for educational purposes only and does not substitute professional medical advice. URO-902 is an investigational therapy not yet approved by the FDA. Neuspera iSNM and penile implants are approved but carry risks that should be discussed with a qualified surgeon. Always consult a licensed healthcare provider for diagnosis and treatment decisions.
Author and Reviewer
Author – Lori A. Pinke, M.D. Urologist at Adult & Pediatric Urology. Dr. Pinke practices in Sartell and Buffalo, with a special interest in female urology, overactive bladder, and minimally invasive surgical treatments.
Reviewer – Christopher W. Boelter, M.D. Urologist at Adult & Pediatric Urology.
Last updated: May 21, 2026